2024 half year results innovation progress
First half of 2024: Boehringer Ingelheim progresses pipeline at pace and reaches major milestones
Search
AI&Data Science Fellowship Tuebingen
AI&Data Science Fellowship Tuebingen
Partnership to Develop Urea Cycle Disorders Therapy
Boehringer Ingelheim Partners with Thoeris to Investigate a Novel Approach to Treat Urea Cycle Disorders
Hypertension
Click here for more information on Hypertension
Distributing medicine globally with pharmaceutical logistics
From Germany to Australia, here’s what it takes from operations and logistics to ensure patients get their medicine on time, every time.
Ofev®
Ofev® is a prescription medication used to treat people with idiopathic pulmonary fibrosis (IPF) systemic sclerosis-associated interstitial lung disease (SSc-ILD) and other chronic fibrosing interstitial lung diseases with a progressive phenotype
Making a difference with data science
Our Head of Central Data Science, Brigitte Fuhr joined the team to make a difference to patients’ lives.
Reimagining digital healthcare worldwide
How does our digital lab BI X innovate in Ingelheim and Shanghai? Read about success stories based on different ideation processes
SPEVIGO approved expanded indications China US
SPEVIGO® approved for expanded indications in China and the US
Our-position
Potential access to selected medications for appropriate patients with serious, life-threatening diseases unable to participate in a clinical trial
Central Nervous System Diseases
Find out more about our research and development in central nervous system diseases
EFPIA Mission Possible
This new video highlights how treatments once known for type 2 diabetes are now helping to prevent heart failure, stroke or kidney disease.
The Goals to Improve Living with GPP
An article that describes the current goals to improve the lives of those living with generalized pustular psoriasis
Groundbeaking of vaccine production center in France
Boehringer Ingelheim breaks ground on its strategic vaccine production center for veterinary public health
New indications NexGard, NexGard SPECTRA and Broadline
New therapeutic indications for NexGard®, NexGard SPECTRA® and Broadline® approved by EMA
Biopharmaceuticals: large molecules, enormous potential
Researching, developing and manufacturing biopharmaceuticals is a highly complex and lengthy process, but it has enormous potential.
Metalyse®
Fibrinolytic treatment of acute myocardial infarction. Fibrinolytic treatment of acute ischaemic stroke.
Alesion®
Prophylactic treatment of patients with bronchial asthma. Prophylaxis and symptomatic treatment of allergic rhinitis.
Catapresan®
Treatment of hypertension.
Boehringer Ingelheim and GST prepared bring innovation to equine market
Boehringer Ingelheim and Global Stem Cell Technology are prepared to bring groundbreaking innovation to equine market
Boehringer and ZEISS partnership eye diseases
Boehringer Ingelheim and ZEISS join forces to early detect eye diseases and prevent vision loss
Liu
Hear Liu share his experience of being diagnosed with type 2 diabetes and heart disease on the same day and the impact this simultaneous diagnosis has had on his life as he knew it.
meat consumption market trends growth sustainability
In this article, we’re taking a look at global developments while highlighting one of the most important meat markets of the future: the Asian continent.
Partnership Boehringer Ingelheim Lifebit health data
Boehringer Ingelheim and Lifebit announce partnership to capture transformational value of health data
Investment social engagements in Cowtribe veterinary startup
Last-mile veterinary delivery social start-up Cowtribe first investment of Boehringer Ingelheim Social Engagements